In the first quarter, the drug use in public hospitals was 163 billion, down 21.6% YoY

Pharmaceutical Network July 22 Recently, IQVIA released a review of China's hospital pharmaceutical market in the first quarter of 2020, according to IQVIA China Hospital Drug Statistics Report (hospitals s 100 beds), the first quarter of this year due to the impact of the new coronary pneumonia outbreak, china's total hospital pharmaceutical market sales of about 163 billion yuan, while the total sales of China's hospital medicine market in the same period last year is about 206.5 billion yuan, down 21.6 percent year-on-year.
multinationals VS domestic multinationals in the first quarter of 2020 sales reached 50.3 billion yuan, compared with 57.6 billion yuan in the same period last year, down 13.0% YoY, while sales of local enterprises in the first quarter were about 112.7 billion yuan, compared with 148.9 billion yuan in the same period last year, a more significant decline of 25.0% YoY.
multinational sat (rolling full-year data: the specified time node traced back to the 12-month data sum, in this case, the second quarter of 2019 to the first quarter of 2020 sales) annual sales of nearly 231.5 billion yuan, compared with 214.6 billion yuan in the same period last year, a growth rate of 7.7%;
ranked in the top three by MAT annual sales, AstraZeneca, Pfizer and Yangzijiang Pharmaceuticals were among the top three, and last year were among the top three, although the ranking was Pfizer's top, followed by AstraZeneca, which was strongly affected by the outbreak, with most of the top 10 companies leading the way in quarterly sales.
, according to MATT's annual sales, Sanofi became the only company to fall in TOP 10, with MAT growing by 5.8 per cent year-on-year, which some analysts said was largely due to its influence on the larger variety, Porivi.
anti-tumor drugs and immunomodulators affected by the outbreak relatively small IQVIA data show that in the first quarter of 2020, quarterly sales of all categories decreased significantly year-on-year, but under the influence of the expansion of the health insurance catalog and the need for clinical drug use, anti-tumor drugs and immunomodulators were relatively small affected by the outbreak, with a quarterly sales rate of -2.9% yoy to 22.7 billion yuan.
specific products, Yangzijiang Pharmaceuticals' Garonin, up 8.5% year-on-year, ranked first; AstraZeneca's Pumick Su-Shu edged down 0.3% year-on-year to second place; Pfizer's Shubdeep, Stone PharmaceuticalGroup's Emp, and Dongsun Pharmaceuticals were ranked first with 11.6%, 31.8%, respectively. 37.8 per cent in third to fifth place, while AstraZeneca's Terissa (Ositini) in seventh place posted a growth rate of 463.5 per cent, the first time Teresa had made the list, thanks to its approval of first-line medication and the "4 plus 7" collection.
August 2019, Teresa was approved for first-line treatment in adult patients with EGFR mutation-positive advanced or metastatic non-small cell lung cancer (NSCLC), and there are statistics that more than 40% of lung cancer patients in China are non-small cell lung cancer (N) with EGFR gene mutations. SCLC patients, after the use of a generation of EGFR-TKI treatment, more than half of the T790M mutation and drug resistance, Teresa was approved first-line treatment, meaning that patients no longer need to produce drug resistance before using Teresa, which also directly letTerisa's market to be further released.
at the same time, on the other hand, AstraZeneca's Iresha (Gifitini) in the volume of procurement with a 76% range of strong price reduction, to a certain extent to prevent other competitive enterprises into the field of non-small cell lung cancer, on the periphery for Terissa to create a good market atmosphere.
.